Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19
Open Access
- 16 July 2020
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 383 (3), 288-290
- https://doi.org/10.1056/nejmc2013656
Abstract
Patients with coronavirus disease 2019 (Covid-19) have a profound hypercoagulable state, and complicating venous thrombotic events are common.1-3 Abnormalities in coagulation screening measures, including a prolonged activated partial-thromboplastin time (aPTT), have been reported in patients with Covid-19.4 This finding could be seen as a reason to avoid the use of anticoagulation at both therapeutic and prophylactic doses.Keywords
This publication has 4 references indexed in Scilit:
- High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patientsJournal of Thrombosis and Haemostasis, 2020
- High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort studyIntensive Care Medicine, 2020
- Incidence of thrombotic complications in critically ill ICU patients with COVID-19Thrombosis Research, 2020
- Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumoniaJournal of Thrombosis and Haemostasis, 2020